Long-term MRI Findings in Patients With Cerebrotendinous Xanthomatosis Treated With Chenodeoxycholic Acid. 2022

Bianca M L Stelten, and Geert J Lycklama À Nijeholt, and Evelien Hendriks, and Leo A J Kluijtmans, and Ron A Wevers, and Aad Verrips
From the Department of Neurology (B.M.L.S.), Catharina Hospital, Eindhoven; Department of Radiology (G.J.L.N.), Haaglanden Medical Center, The Hague; Department of Neurology (E.H., A.V.), Canisius Wilhelmina Hospital; and Department of Laboratory Medicine (L.A.J.K., R.A.W.), Translational Metabolic Laboratory, Radboud University Medical Center, Nijmegen, the Netherlands. bianca.stelten@catharinaziekenhuis.nl.

To describe long-term follow-up brain MRI findings in patients with cerebrotendinous xanthomatosis (CTX) treated with chenodeoxycholic acid (CDCA). Of a cohort of 79 Dutch patients with CTX, we retrospectively reviewed brain MRI findings of patients at diagnosis (before the start of treatment) and after long-term follow-up (7-27 years) in 12 patients. In addition, we report on 2 families with remarkable brain MRI findings. MRI abnormalities showed progression in all 7 patients diagnosed at 24 years or older and only in 1 of 5 patients diagnosed younger than 24 years. MRI findings in the other patients diagnosed younger than 24 years were normal at baseline and remained normal even after follow-up of more than 25 years. The total MRI scores at baseline were 2 and 19 and at follow-up 4 and 37, respectively, for patients diagnosed before or after the age of 24 years, despite a comparable number of treatment years. MRI findings are fully in line with our long-term treatment effect article, emphasizing the importance of early diagnosis and treatment in CTX. Expanding the spectrum of brain MRI findings (including the finding of a posterior leukoencephalopathy) leads to a better understanding of the heterogeneity of this treatable disease.

UI MeSH Term Description Entries
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D002635 Chenodeoxycholic Acid A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones. Chenic Acid,Chenodeoxycholate,Chenodiol,Gallodesoxycholic Acid,Chenique Acid,Chenix,Chenofalk,Chenophalk,Henohol,Quenobilan,Quenocol,Sodium Chenodeoxycholate,Acid, Chenic,Acid, Chenique,Acid, Chenodeoxycholic,Acid, Gallodesoxycholic,Chenodeoxycholate, Sodium
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults
D019294 Xanthomatosis, Cerebrotendinous An autosomal recessive lipid storage disorder due to mutation of the gene CYP27A1 encoding a CHOLESTANETRIOL 26-MONOOXYGENASE. It is characterized by large deposits of CHOLESTEROL and CHOLESTANOL in various tissues resulting in xanthomatous swelling of tendons, early CATARACT, and progressive neurological symptoms. Van Bogaert-Scherer-Epstein Disease,Cerebral Cholesterinosis,Cerebrotendinous Xanthomatosis,Bogaert-Scherer-Epstein Disease, Van,Cerebral Cholesterinoses,Cerebrotendinous Xanthomatoses,Disease, Van Bogaert-Scherer-Epstein,Van Bogaert Scherer Epstein Disease,Xanthomatoses, Cerebrotendinous

Related Publications

Bianca M L Stelten, and Geert J Lycklama À Nijeholt, and Evelien Hendriks, and Leo A J Kluijtmans, and Ron A Wevers, and Aad Verrips
December 1984, The New England journal of medicine,
Bianca M L Stelten, and Geert J Lycklama À Nijeholt, and Evelien Hendriks, and Leo A J Kluijtmans, and Ron A Wevers, and Aad Verrips
October 1985, Annals of neurology,
Bianca M L Stelten, and Geert J Lycklama À Nijeholt, and Evelien Hendriks, and Leo A J Kluijtmans, and Ron A Wevers, and Aad Verrips
January 2013, Clinical neuropharmacology,
Bianca M L Stelten, and Geert J Lycklama À Nijeholt, and Evelien Hendriks, and Leo A J Kluijtmans, and Ron A Wevers, and Aad Verrips
March 2013, Calcified tissue international,
Bianca M L Stelten, and Geert J Lycklama À Nijeholt, and Evelien Hendriks, and Leo A J Kluijtmans, and Ron A Wevers, and Aad Verrips
March 1994, Journal of the Formosan Medical Association = Taiwan yi zhi,
Bianca M L Stelten, and Geert J Lycklama À Nijeholt, and Evelien Hendriks, and Leo A J Kluijtmans, and Ron A Wevers, and Aad Verrips
March 2001, Neurology,
Bianca M L Stelten, and Geert J Lycklama À Nijeholt, and Evelien Hendriks, and Leo A J Kluijtmans, and Ron A Wevers, and Aad Verrips
February 1999, Metabolism: clinical and experimental,
Bianca M L Stelten, and Geert J Lycklama À Nijeholt, and Evelien Hendriks, and Leo A J Kluijtmans, and Ron A Wevers, and Aad Verrips
January 2019, Turk pediatri arsivi,
Bianca M L Stelten, and Geert J Lycklama À Nijeholt, and Evelien Hendriks, and Leo A J Kluijtmans, and Ron A Wevers, and Aad Verrips
September 1975, Biochemical medicine,
Bianca M L Stelten, and Geert J Lycklama À Nijeholt, and Evelien Hendriks, and Leo A J Kluijtmans, and Ron A Wevers, and Aad Verrips
January 2013, Journal of neurology,
Copied contents to your clipboard!